Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

Pages

26873 items
12:34 PM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the Phase IIa COMBAT/KEYNOTE-202 trial showing that BL-8040 plus Keytruda pembrolizumab led to a disease control rate (DCR) of 34.5%, including one partial response and nine cases...
11:17 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Proteostasis' doublet CF therapy improves lung function in Phase I

Proteostasis Therapeutics Inc. (NASDAQ:PTI) reported that its doublet cystic fibrosis therapy improved percent predicted forced expiratory volume in 1 second (ppFEV1) and sweat chloride levels in a Phase I trial. The doublet therapy comprised CF...
11:13 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Keytruda, Inlyta combo headed for first-line RCC submissions

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab in combination with Inlyta axitinib met the primary endpoints vs. Sutent sunitinib in the Phase III KEYNOTE-426 trial as first-line treatment of renal cell carcinoma. Merck plans...
10:59 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Opdivo misses survival endpoint in Phase III for SCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said Opdivo nivolumab missed the primary endpoint of improving overall survival (OS) in the Phase III CheckMate -331 trial to treat small cell lung cancer in patients who relapsed following platinum-based...
10:38 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Eisai, Purdue insomnia candidate meets in second Phase III

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) said lemborexant met the primary and secondary endpoints in the Phase III SUNRISE 2 trial to treat insomnia. The trial is the second Phase III...
10:25 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Taris' TAR-302 reduces daily incontinence episodes by 75% in Phase Ib

Taris Biomedical LLC (Lexington, Mass.) reported Phase Ib data in August showing that TAR-302 reduced mean daily incontinence episodes by 75% at day 42 in idiopathic overactive bladder (OAB) patients who were experiencing an average...
10:21 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Celgene's Otezla meets in Phase III for scalp psoriasis

Celgene Corp. (NASDAQ:CELG) said Otezla apremilast met the primary endpoint in the Phase III STYLE trial to treat moderate to severe plaque psoriasis of the scalp. A significantly greater proportion of patients who received twice-daily...
10:17 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Novo's oral GLP-1 analog meets in Japanese Phase IIIa for Type II diabetes

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported that oral semaglutide met the primary safety endpoint in the Japanese Phase IIIa PIONEER 10 trial to treat Type II diabetes. The open-label trial evaluated once-daily 3, 7...
10:16 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Orphazyme seeking path forward for arimoclomol in NPC after Phase II/III miss

Orphazyme A/S (CSE:ORPHA) said arimoclomol missed the primary endpoints in a Phase II/III trial to treat Niemann-Pick disease type C (NPC). The company plans to meet with FDA and EMA to determine next steps for...
10:14 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Viking's VK5211 meets primary in Phase II for acute hip fracture

Viking Therapeutics Inc. (NASDAQ:VKTX) said VK5211 met the primary endpoint of increasing lean body mass from baseline to week 12 vs. placebo in a Phase II trial in patients recovering from acute hip fracture surgery....

Pages